Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized Controlled Clinical Study of Venetoclax Combined With Azacitidine and Mitoxantrone Hydrochloride Liposome Versus Idarubicin Combined With Cytarabine "3+7" in the Treatment of Newly Diagnosed AML

NCT07486479 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT07486479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07486479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized Controlled Clinical Study of Venetoclax Combined With Azacitidine and Mitoxantrone Hydrochloride Liposome Versus Idarubicin Combined With Cytarabine "3+7" in the Treatment of Newly Diagnosed AML
Lead sponsor
The First Affiliated Hospital of Soochow University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 10, 2026
Completion date
December 31, 2027
Enrollment
204 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)